Display options
Cite
Barazetti JF, Jucoski TS, Carvalho TM, et al. From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells. Cancers (Basel). 2021;13(15)doi: 10.3390/cancers13153688.
Barazetti, J. F., Jucoski, T. S., Carvalho, T. M., Veiga, R. N., Kohler, A. F., Baig, J., Al Bizri, H., Gradia, D. F., Mader, S., & Carvalho de Oliveira, J. (2021). From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells. Cancers, 13(15), . https://doi.org/10.3390/cancers13153688
Barazetti, Jéssica Fernanda, et al. "From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells." Cancers vol. 13,15 (2021). doi: https://doi.org/10.3390/cancers13153688
Barazetti JF, Jucoski TS, Carvalho TM, Veiga RN, Kohler AF, Baig J, Al Bizri H, Gradia DF, Mader S, Carvalho de Oliveira J. From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells. Cancers (Basel). 2021 Jul 22;13(15). doi: 10.3390/cancers13153688. PMID: 34359587; PMCID: PMC8345104.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Jul 22;13(15). doi: 10.3390/cancers13153688.

From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells.

Cancers

Jéssica Fernanda Barazetti, Tayana Shultz Jucoski, Tamyres Mingorance Carvalho, Rafaela Nasser Veiga, Ana Flávia Kohler, Jumanah Baig, Hend Al Bizri, Daniela Fiori Gradia, Sylvie Mader, Jaqueline Carvalho de Oliveira

Affiliations

  1. Post-Graduation Program in Genetics, Department of Genetics, Federal University of Parana, Curitiba 81530-000, Parana, Brazil.
  2. Department of Biochemistry and Molecular Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada.
  3. Institute for Research in Immunology and Cancer, University of Montreal, Montreal, QC H3T 1J4, Canada.

PMID: 34359587 PMCID: PMC8345104 DOI: 10.3390/cancers13153688

Abstract

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality among women. Two thirds of patients are classified as hormone receptor positive, based on expression of estrogen receptor alpha (ERα), the main driver of breast cancer cell proliferation, and/or progesterone receptor, which is regulated by ERα. Despite presenting the best prognosis, these tumors can recur when patients acquire resistance to treatment by aromatase inhibitors or antiestrogen such as tamoxifen (Tam). The mechanisms that are involved in Tam resistance are complex and involve multiple signaling pathways. Recently, roles for microRNAs and lncRNAs in controlling ER expression and/or tamoxifen action have been described, but the underlying mechanisms are still little explored. In this review, we will discuss the current state of knowledge on the roles of microRNAs and lncRNAs in the main mechanisms of tamoxifen resistance in hormone receptor positive breast cancer. In the future, this knowledge can be used to identify patients at a greater risk of relapse due to the expression patterns of ncRNAs that impact response to Tam, in order to guide their treatment more efficiently and possibly to design therapeutic strategies to bypass mechanisms of resistance.

Keywords: breast cancer; endocrine resistance; estrogen receptor; lncRNA; microRNA; ncRNA; tamoxifen

References

  1. Oncogene. 2019 Jul;38(28):5551-5565 - PubMed
  2. BMC Cancer. 2018 Aug 24;18(1):850 - PubMed
  3. Am J Transl Res. 2015 Oct 15;7(10):2115-26 - PubMed
  4. Int J Oncol. 2019 Mar;54(3):1033-1042 - PubMed
  5. Mol Med Rep. 2018 Jul;18(1):1120-1126 - PubMed
  6. BMC Cancer. 2016 Jul 04;16:378 - PubMed
  7. J Biol Chem. 2017 Aug 18;292(33):13551-13564 - PubMed
  8. PLoS Genet. 2013 Jun;9(6):e1003569 - PubMed
  9. Breast Cancer Res Treat. 2019 Jun;175(2):353-368 - PubMed
  10. Aging (Albany NY). 2020 Oct 24;12(20):20658-20683 - PubMed
  11. Stem Cells. 2016 Aug;34(8):2052-62 - PubMed
  12. Cancer Lett. 2017 Mar 1;388:230-238 - PubMed
  13. J Biol Chem. 2008 Oct 31;283(44):29897-903 - PubMed
  14. Cell Physiol Biochem. 2016;40(3-4):707-715 - PubMed
  15. Biochem Biophys Res Commun. 2016 Sep 2;477(4):768-773 - PubMed
  16. Int J Mol Med. 2020 Feb;45(2):497-509 - PubMed
  17. Cell Physiol Biochem. 2018;51(4):1518-1532 - PubMed
  18. Front Pharmacol. 2017 Dec 13;8:902 - PubMed
  19. Cancer Res. 2008 Feb 1;68(3):852-60 - PubMed
  20. Breast Cancer Res Treat. 2015 Jan;149(1):81-9 - PubMed
  21. Cell Rep. 2020 Jun 9;31(10):107753 - PubMed
  22. Nat Rev Cancer. 2009 Sep;9(9):631-43 - PubMed
  23. Biomed Res Int. 2016;2016:8797206 - PubMed
  24. Sci Rep. 2015 Mar 04;5:8735 - PubMed
  25. Sci Rep. 2015 Aug 10;5:13170 - PubMed
  26. Drug Des Devel Ther. 2021 Jan 22;15:245-257 - PubMed
  27. Cell Oncol (Dordr). 2019 Oct;42(5):627-644 - PubMed
  28. Breast Cancer. 2021 Jan;28(1):175-186 - PubMed
  29. Aging (Albany NY). 2019 Aug 10;11(15):5705-5725 - PubMed
  30. Oncol Lett. 2020 Nov;20(5):160 - PubMed
  31. Ther Adv Med Oncol. 2017 May;9(5):335-346 - PubMed
  32. Cancer Chemother Pharmacol. 2017 Feb;79(2):327-337 - PubMed
  33. Biomed Pharmacother. 2016 Feb;77:37-44 - PubMed
  34. Cell. 2010 Aug 6;142(3):409-19 - PubMed
  35. Cancer Res. 2013 Nov 15;73(22):6554-62 - PubMed
  36. Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):716-21 - PubMed
  37. Tumour Biol. 2017 Jun;39(6):1010428317705790 - PubMed
  38. Nat Biotechnol. 2011 Nov 13;30(1):99-104 - PubMed
  39. Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2838-2846 - PubMed
  40. Oncogene. 2011 Feb 17;30(7):822-31 - PubMed
  41. Oncol Rep. 2019 Mar;41(3):1901-1910 - PubMed
  42. Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4362-4368 - PubMed
  43. J Cancer. 2020 Mar 13;11(12):3416-3423 - PubMed
  44. Nat Rev Drug Discov. 2017 Mar;16(3):203-222 - PubMed
  45. Int J Mol Sci. 2019 Jan 14;20(2): - PubMed
  46. Oncogene. 2012 Jan 5;31(1):39-47 - PubMed
  47. Nat Commun. 2016 Sep 26;7:12791 - PubMed
  48. Onco Targets Ther. 2017 Sep 07;10:4369-4378 - PubMed
  49. Cancer Lett. 2018 Oct 10;434:1-10 - PubMed
  50. Cell Signal. 2020 Apr;68:109536 - PubMed
  51. Cell Death Dis. 2016 Nov 3;7(11):e2454 - PubMed
  52. Sci Rep. 2015 Jan 06;5:7641 - PubMed
  53. Nat Rev Genet. 2020 Feb;21(2):102-117 - PubMed
  54. Int J Cancer. 2019 Aug 1;145(3):842-856 - PubMed
  55. Cell Rep. 2016 May 31;15(9):2025-37 - PubMed
  56. Nature. 2012 Sep 6;489(7414):101-8 - PubMed
  57. J Natl Cancer Inst. 2010 May 19;102(10):706-21 - PubMed
  58. PLoS One. 2019 May 23;14(5):e0217181 - PubMed
  59. Mol Cancer. 2017 Oct 17;16(1):161 - PubMed
  60. CA Cancer J Clin. 2021 May;71(3):209-249 - PubMed
  61. J Exp Clin Cancer Res. 2019 Oct 10;38(1):414 - PubMed
  62. Nat Genet. 2000 May;25(1):19-21 - PubMed
  63. Cells. 2020 Jan 07;9(1): - PubMed
  64. Cancer Res. 2018 Sep 1;78(17):4915-4928 - PubMed
  65. Cancer Med. 2018 Dec;7(12):6137-6146 - PubMed
  66. Cancer Lett. 2009 Aug 8;280(2):184-91 - PubMed
  67. Lancet. 2005 May 14-20;365(9472):1687-717 - PubMed
  68. J Breast Cancer. 2017 Mar;20(1):35-44 - PubMed
  69. Cancer Manag Res. 2020 Mar 10;12:1771-1777 - PubMed
  70. Int J Mol Sci. 2016 Aug 19;17(8): - PubMed
  71. Biomed Pharmacother. 2018 Nov;107:117-128 - PubMed
  72. J Biol Chem. 2008 Nov 7;283(45):31079-86 - PubMed
  73. Oncotarget. 2016 Jul 5;7(27):42261-42273 - PubMed
  74. J Hematol Oncol. 2019 Jul 24;12(1):81 - PubMed
  75. BMC Cancer. 2015 Jul 24;15:540 - PubMed
  76. Int J Cancer. 2003 Nov 10;107(3):353-8 - PubMed
  77. Genome Res. 2012 Sep;22(9):1775-89 - PubMed
  78. Nat Rev Cancer. 2011 Nov 24;11(12):849-64 - PubMed
  79. Cell Rep. 2019 Jul 2;28(1):104-118.e8 - PubMed
  80. PLoS One. 2016 Dec 15;11(12):e0168406 - PubMed
  81. Nat Rev Endocrinol. 2011 Aug 16;7(12):715-26 - PubMed
  82. Science. 2005 Sep 2;309(5740):1559-63 - PubMed
  83. J Pathol. 2021 Jun;254(2):185-198 - PubMed
  84. PLoS One. 2017 Feb 2;12(2):e0167969 - PubMed
  85. Oncogene. 2015 Jul 23;34(30):3895-907 - PubMed
  86. Cell. 2007 Jun 29;129(7):1311-23 - PubMed
  87. Br J Cancer. 2004 May 17;90(10):1942-8 - PubMed
  88. J Gene Med. 2019 Jan;21(1):e3065 - PubMed
  89. Nature. 2010 Apr 15;464(7291):1071-6 - PubMed
  90. Oncotarget. 2016 Sep 20;7(38):61166-61182 - PubMed
  91. J Cell Physiol. 2019 Mar;234(3):2880-2894 - PubMed
  92. Med Sci Monit. 2016 Oct 21;22:3860-3867 - PubMed
  93. Horm Cancer. 2010 Dec;1(6):306-19 - PubMed
  94. Int J Oncol. 2015 Jan;46(1):205-14 - PubMed
  95. Breast. 2019 Feb;43:31-38 - PubMed
  96. Cell Signal. 2018 Jan;42:165-175 - PubMed
  97. Annu Rev Med. 2011;62:233-47 - PubMed
  98. Prog Mol Biol Transl Sci. 2016;144:539-562 - PubMed
  99. Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:193-206 - PubMed
  100. N Engl J Med. 2017 Nov 9;377(19):1836-1846 - PubMed
  101. Cancer Biother Radiopharm. 2018 Aug;33(6):241-251 - PubMed
  102. Oncotarget. 2015 Oct 13;6(31):31944-57 - PubMed
  103. Mol Biol (Mosk). 2016 Sep-Oct;50(5):821-827 - PubMed
  104. Front Oncol. 2015 Feb 16;5:24 - PubMed
  105. Open Med (Wars). 2020 Dec 15;16(1):68-80 - PubMed
  106. Mol Cancer. 2020 Feb 4;19(1):22 - PubMed
  107. Biochem Biophys Res Commun. 2017 Feb 5;483(2):840-846 - PubMed
  108. Cancer Gene Ther. 2010 Aug;17(8):523-31 - PubMed
  109. Nucleic Acids Res. 2008 Jan;36(1):76-93 - PubMed
  110. Clin Breast Cancer. 2017 Apr;17(2):79-90 - PubMed
  111. Breast Cancer Res Treat. 2014 Jul;146(1):85-97 - PubMed
  112. Nat Genet. 2011 Jun 05;43(7):621-9 - PubMed
  113. Nat Commun. 2020 Nov 2;11(1):5513 - PubMed
  114. Life Sci. 2016 Mar 15;149:104-13 - PubMed
  115. J Pathol. 2010 May;221(1):3-12 - PubMed
  116. Nat Rev Cancer. 2018 Jun;18(6):377-388 - PubMed
  117. DNA Cell Biol. 2016 Sep;35(9):459-70 - PubMed
  118. Mol Cell Biol. 2019 Nov 12;39(23): - PubMed
  119. Endocrinology. 2005 Dec;146(12):5474-84 - PubMed
  120. Eur Rev Med Pharmacol Sci. 2017 Feb;21(4):706-714 - PubMed
  121. Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):299-313 - PubMed
  122. Mol Med. 2011;17(11-12):1233-41 - PubMed
  123. Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1563-1573 - PubMed
  124. Oncotarget. 2016 Mar 22;7(12):13902-16 - PubMed
  125. EMBO J. 2012 Feb 1;31(3):522-33 - PubMed
  126. Cell Physiol Biochem. 2018;46(4):1643-1649 - PubMed
  127. J Mol Biol. 2013 Oct 9;425(19):3707-22 - PubMed
  128. Bioessays. 2002 Mar;24(3):244-54 - PubMed
  129. Brief Bioinform. 2019 Mar 22;20(2):551-564 - PubMed
  130. J Cell Biochem. 2019 Aug;120(8):12966-12976 - PubMed
  131. Breast Cancer Res. 2012 Apr 04;14(2):R57 - PubMed
  132. J Pathol. 2014 Aug;233(4):368-79 - PubMed
  133. Mol Cell. 2011 Nov 18;44(4):667-78 - PubMed
  134. Chin J Cancer. 2017 Jun 24;36(1):52 - PubMed
  135. Front Cell Dev Biol. 2019 Oct 02;7:217 - PubMed
  136. Clin Cancer Res. 1997 Jun;3(6):849-54 - PubMed
  137. Mol Cancer. 2015 Dec 15;14:208 - PubMed
  138. Mol Cancer. 2010 Dec 20;9:317 - PubMed
  139. Development. 2013 Mar;140(6):1184-95 - PubMed
  140. Onco Targets Ther. 2018 Nov 09;11:8001-8012 - PubMed
  141. Cell Physiol Biochem. 2014;33(5):1557-67 - PubMed
  142. Oncologist. 2018 May;23(5):528-539 - PubMed
  143. Science. 2010 Aug 6;329(5992):689-93 - PubMed
  144. J Mol Endocrinol. 2017 Jan;58(1):R15-R31 - PubMed
  145. FASEB J. 2018 Feb;32(2):588-600 - PubMed
  146. Nat Commun. 2021 Mar 19;12(1):1786 - PubMed
  147. Front Endocrinol (Lausanne). 2020 Jul 31;11:506 - PubMed
  148. Cancer Res. 2011 Apr 15;71(8):2926-37 - PubMed
  149. Mol Endocrinol. 2007 Sep;21(9):2112-23 - PubMed
  150. Oncotarget. 2017 Oct 6;8(59):99978-99989 - PubMed
  151. Lancet. 2017 Mar 18;389(10074):1134-1150 - PubMed
  152. Sci Rep. 2019 Jul 1;9(1):9430 - PubMed
  153. J Natl Cancer Inst. 2018 Apr 1;110(4): - PubMed
  154. Mol Cell Endocrinol. 2011 Mar 1;334(1-2):76-82 - PubMed
  155. Tumour Biol. 2016 Nov;37(11):14733-14743 - PubMed
  156. Nat Commun. 2015 Jul 17;6:7769 - PubMed
  157. J Drug Target. 2021 Aug;29(7):742-753 - PubMed
  158. Cancer Cell Int. 2021 Apr 29;21(1):240 - PubMed
  159. Nature. 2009 Mar 12;458(7235):223-7 - PubMed
  160. Biochem J. 2018 Jun 11;475(11):1939-1954 - PubMed
  161. Int J Oncol. 2021 Jan;58(1):33-44 - PubMed
  162. Cancer Lett. 2011 Dec 26;313(1):26-43 - PubMed
  163. Breast Cancer Res Treat. 2014 Sep;147(2):423-31 - PubMed
  164. Biochemistry (Mosc). 2018 May;83(5):603-611 - PubMed
  165. Biomed Pharmacother. 2019 Feb;110:400-408 - PubMed
  166. Sci Rep. 2018 Oct 23;8(1):15670 - PubMed
  167. J Breast Cancer. 2020 Jan 16;23(2):129-140 - PubMed
  168. Cancer Discov. 2015 Sep;5(9):944-59 - PubMed
  169. Cancer Treat Rev. 2012 Oct;38(6):698-707 - PubMed
  170. Endocr Relat Cancer. 2004 Dec;11(4):643-58 - PubMed
  171. Signal Transduct Target Ther. 2020 Jun 19;5(1):101 - PubMed
  172. J Natl Cancer Inst. 2004 Jun 16;96(12):926-35 - PubMed
  173. Int J Cancer. 2002 May 1;99(1):35-42 - PubMed
  174. Science. 2012 Dec 14;338(6113):1469-72 - PubMed
  175. Eur J Pharm Sci. 2018 Jul 30;120:73-88 - PubMed
  176. Cell Biol Toxicol. 2017 Apr;33(2):183-195 - PubMed
  177. Mol Cell Endocrinol. 2010 Jul 29;323(2):268-76 - PubMed
  178. Front Oncol. 2017 Mar 15;7:26 - PubMed
  179. Cell. 2013 Jul 3;154(1):240-51 - PubMed
  180. Bioorg Chem. 2017 Apr;71:257-274 - PubMed
  181. Int J Clin Exp Pathol. 2020 Oct 01;13(10):2455-2473 - PubMed
  182. Sci Rep. 2020 Aug 24;10(1):14145 - PubMed
  183. J Lipid Res. 2018 Dec;59(12):2297-2307 - PubMed
  184. Nature. 2011 Aug 28;477(7364):295-300 - PubMed
  185. Oncol Lett. 2018 Mar;15(3):3532-3539 - PubMed
  186. Biomed Pharmacother. 2017 Dec;96:634-641 - PubMed
  187. Mol Cell. 2014 Mar 20;53(6):1005-19 - PubMed
  188. FEBS Lett. 2017 Jan;591(2):382-392 - PubMed
  189. PLoS One. 2013 Apr 23;8(4):e62334 - PubMed
  190. Oncogene. 2016 May;35(21):2746-55 - PubMed
  191. Onco Targets Ther. 2015 Sep 21;8:2657-64 - PubMed
  192. Cell Physiol Biochem. 2018;50(1):136-149 - PubMed

Publication Types